Peptides by condition · Heart, kidneys and lungs
Peptides studied for COVID-19
Checked against our study pages and the FDA labelsPublished by PepVault
Our library holds 7 study pages on COVID-19: 6 in people (all meta-analyses or randomized trials), and 1 in animals. They studied 5 compounds, with this many study pages each: VIP 2, Thymosin Alpha-1 2, LL-37 1, Larazotide 1 and Thymosin Beta-4 1.
What the research on COVID-19 looks like
Read the design before any result. Of these 7 studies, 1 was in animals and 6 were in people, the largest with 238 people. A finding in cells or animals is where research starts, and many such findings do not hold up in people.
COVID-19 is the illness caused by the SARS-CoV-2 coronavirus. Most people recover at home, but in some it inflames the lungs badly enough to need oxygen or a breathing machine. The peptide research on it comes from the pandemic years: hospital trials that added a peptide to standard care, pooled analyses of those trials, a mouse study of a related coronavirus, and a small trial in children with MIS-C, a rare inflammation of the whole body that can follow the infection weeks later.
Hospital trials count deaths, recovery from respiratory failure and days in hospital, and some time how long it took for the virus test to turn negative. The pooled analyses combine those counts across trials of different sizes and designs.
Many COVID-19 trials were small, run quickly and open-label, meaning everyone knew who got the drug, and standard care changed during the pandemic, so a result from one wave may not hold in another. A larger placebo-controlled trial deserves more weight than an early pilot, and a mouse coronavirus is a different virus.
The 7 studies, by compound
Grouped by the compound each study is filed under, and within each, strongest design first. Each line gives the design, who was studied, how many and the year, before the finding.
VIP
2 in peopleFor COVID-19, 2 of our study pages are filed under VIP: 2 randomized trials in people. The largest in people enrolled 196 people and was published in 2022. They were published from 2022 to 2025, in Crit Care Med and Med Princ Pract.
VIP (vasoactive intestinal peptide) has no FDA-approved product: Drugs@FDA lists no application for it or for aviptadil.
- Randomized trial in people · 196 people · 2022VIP (aviptadil) missed its main goal in critical COVID-19 trial
- Randomized trial in people · 80 people · 2025VIP (aviptadil): discharge at 7.8 vs 10 days in COVID-19
Thymosin Alpha-1
2 in peopleFor COVID-19, 2 of our study pages are filed under Thymosin Alpha-1: 1 meta-analysis and 1 randomized trial in people. The largest in people enrolled 194 people and was published in 2023. All were published in 2023, in Inflammopharmacology and Int Immunopharmacol.
Thymosin alpha-1 (thymalfasin) has no FDA-approved product: Drugs@FDA lists no application for it.
- Meta-analysis in people · 2023Thymosin alpha-1: lower COVID-19 death risk (RR 0.59) in meta-analysis
- Randomized trial in people · 194 people · 2023Thymosin alpha-1: 3 deaths vs 7 in dialysis COVID-19 pilot so far
LL-37
1 in peopleFor COVID-19, 1 of our study pages is filed under LL-37: 1 randomized trial in people. It enrolled 238 people and was published in 2023, in J Med Virol.
LL-37 has no FDA-approved product: Drugs@FDA lists no application for it.
- Randomized trial in people · 238 people · 2023LL-37 taken by mouth shortened time to negative COVID-19 RNA test
Larazotide
1 in peopleFor COVID-19, 1 of our study pages is filed under Larazotide: 1 randomized trial in people. It enrolled 12 people and was published in 2025, in Sci Transl Med.
Larazotide has no FDA-approved product: Drugs@FDA lists no application for it.
- Randomized trial in people · 12 people · 2025Larazotide sped gut symptom recovery in children with post-COVID MISC
Thymosin Beta-4
1 in animalsFor COVID-19, 1 of our study pages is filed under Thymosin Beta-4: 1 animal study (mice). It was published in 2021, in Mediators Inflamm.
Thymosin beta-4 has no FDA-approved product: Drugs@FDA lists no application for it.
- Animal study in mice · 2021Thymosin beta-4 raised survival in mice with a coronavirus infection
Side by side
For the 5 compounds on this page: studies in people, studies in animals or cells, the size of the largest study in people, and the FDA status from the labels our status pages read (a dash where they hold no record).
| Compound | In people | Animals or cells | Largest in people | FDA |
|---|---|---|---|---|
| VIP | 2 | 0 | 196 | Not approved |
| Thymosin Alpha-1 | 2 | 0 | 194 | Not approved |
| LL-37 | 1 | 0 | 238 | Not approved |
| Larazotide | 1 | 0 | 12 | Not approved |
| Thymosin Beta-4 | 0 | 1 | — | Not approved |
- In people
- 2
- Animals or cells
- 0
- Largest in people
- 196
- FDA
- Not approved
- In people
- 2
- Animals or cells
- 0
- Largest in people
- 194
- FDA
- Not approved
- In people
- 1
- Animals or cells
- 0
- Largest in people
- 238
- FDA
- Not approved
- In people
- 1
- Animals or cells
- 0
- Largest in people
- 12
- FDA
- Not approved
- In people
- 0
- Animals or cells
- 1
- Largest in people
- —
- FDA
- Not approved
What the studies did not show
Each study page names its own limits. These are the questions still open, in the study pages’ words.
- VIP (aviptadil) missed its main goal in critical COVID-19 trialThe trial failed its main outcome, so the survival and subgroup results are secondary findings that can't settle the question alone. It studied only hospitalized patients with critical COVID-19 who got a short IV course.
- Thymosin Alpha-1: Thymosin alpha-1: lower COVID-19 death risk (RR 0.59) in meta-analysisThe pooled studies differed a lot from each other (I2 of 84% for the death result), and the effect depended on study size and sex. The authors say randomized trials are still needed to confirm the finding.
- Larazotide sped gut symptom recovery in children with post-COVID MISCThis was a very small, early-stage trial of 12 children, so its safety and benefit results are preliminary. The links between spike levels, inflammation and symptoms are correlations and don't show cause.
- Thymosin Beta-4: Thymosin beta-4 raised survival in mice with a coronavirus infectionThis was a mouse study using a mouse coronavirus, not SARS-CoV-2 or any virus that infects people, so it is not a human result. It tested the full 43-residue recombinant human Tβ4 protein, not the shorter TB-500 fragment.
This page is a reading of published studies, not medical advice. A diagnosis, and what to do about it, is a conversation with a clinician.
Questions
Which peptides have been studied for COVID-19?
Our 7 study pages on COVID-19 are filed under 5 compounds, with this many each: VIP 2, Thymosin Alpha-1 2, LL-37 1, Larazotide 1 and Thymosin Beta-4 1. VIP and Thymosin Alpha-1 have the most, 2 each.
Have any been tested in people with COVID-19?
Yes: 6 of the 7 were in people, all of them meta-analyses or randomized trials (VIP, Thymosin Alpha-1, LL-37 and Larazotide). The largest enrolled 238 people: “LL-37 taken by mouth shortened time to negative COVID-19 RNA test” (2023).
Is any peptide FDA-approved for COVID-19?
Not by the labels our status pages read: of the 5 compounds here with an FDA record, none has a use tied to COVID-19.
How large were the studies in people on COVID-19?
Of the 6 in people, 5 give their size on our pages: 3 had 100 to 999 and 2 had fewer than 100. The largest, a randomized trial from 2023, enrolled 238.
What did the animal and cell studies on COVID-19 use?
1 animal study (mice), filed under Thymosin Beta-4. A result in animals or cells shows what to test next, not what happens in a person.
What is the newest study on COVID-19 here?
Of our study pages on COVID-19, the newest is “VIP (aviptadil): discharge at 7.8 vs 10 days in COVID-19”, a randomized trial in people published in 2025.
How this page was built
A study page is listed here only where we read its question, design and finding and the study was about this condition: its subjects had the condition, or were an animal or cell model of it, and the study gave them the compound. A study that only mentions the condition is not listed.
Studies are grouped by the compound each is filed under and ordered by design: meta-analyses and randomized trials in people first, then other studies in people, then animals, then cells, and within a group by size and then by year. The FDA status comes from the labels our legal-status and brand pages read.